| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 43 |
| 1 | IPILIMUMAB | 18 |
| 2 | CARBOPLATIN | 8 |
| 3 | CABOZANTINIB | 5 |
| 4 | DURVALUMAB | 4 |
| 5 | ETOPOSIDE | 3 |
| 6 | AMLODIPINE BESYLATE | 2 |
| 7 | AXICABTAGENE CILOLEUCEL | 2 |
| 8 | BISOPROLOL FUMARATE | 2 |
| 9 | BLINATUMOMAB | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-BVZR | 1 | 0.0014 |
| 1 | ESTAZOLAM | 1 | 0.0005 |
| 2 | BREXUCABTAGENE AUTOLEUCEL | 1 | 0.0005 |
| 3 | TREMELIMUMAB | 2 | 0.0005 |
| 4 | NIVOLUMAB | 43 | 0.0004 |
| 5 | IPILIMUMAB | 18 | 0.0004 |
| 6 | GLYCERIN SUPPOSITORY | 1 | 0.0004 |
| 7 | GLYCERIN SUPPOSITORIES | 1 | 0.0004 |
| 8 | SITAGLIPTIN PHOSPHATE | 1 | 0.0004 |
| 9 | LEMBOREXANT | 1 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 43 | 0.0004 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 20 | 0.0004 |
| 2 | CD19-directed Chimeric Antigen Receptor [EPC] | 2 | 0.0002 |
| 3 | Osmotic Diuretic [EPC] | 1 | 0.0002 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 4 | 0.0002 |
| 5 | Non-Standardized Plant Allergenic Extract [EPC] | 1 | 0.0001 |
| 6 | Orexin Receptor Antagonist [EPC] | 1 | 0.0001 |
| 7 | Polyene Antifungal [EPC] | 2 | 0.0000 |
| 8 | Platinum-based Drug [EPC] | 11 | 0.0000 |
| 9 | Topoisomerase Inhibitor [EPC] | 3 | 0.0000 |